|
Glecaprevir with pibrentasvir for chronic hepatitis C infection, genotypes 1, 2, 3, 4, 5 and 6 |
NIHR HSRIC |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Glecaprevir with pibrentasvir for chronic hepatitis C infection, genotypes 1, 2, 3, 4, 5 and 6. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Hepatitis C is a virus that causes inflammation of the liver. The virus is most commonly passed on by needles contaminated with infected blood, but it is also occasionally spread through unprotected sex. Most people with hepatitis C will have it for many years and they may or may not have symptoms. If the virus is untreated, it can lead to serious liver disease, such as liver cirrhosis and cancer.
Current treatments of hepatitis C include a combination of drugs so that viral resistance doesn't develop to one specific drug. The combination of therapies used may depend on the type of hepatitis C virus, and some drugs require injection.
Glecaprevir and pibrentasvir are two new drugs combined in a single tablet taken by mouth once a day for 8-12 weeks. Glecaprevir and pibrentasvir target different aspects of the hepatitis C virus and this drug combination aims to treat all known types of hepatitis C.
Glecaprevir with pibrentasvir is being studied to determine how well it works and whether it is safe to use in those with hepatitis C infection. If licensed, glencaprevir with pibrentasvir will offer an injection free treatment option for patients with hepatitis C. Indexing Status Subject indexing assigned by CRD MeSH Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mouth Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000681 Date abstract record published 25/05/2016 |
|
|
|